| Iopidine (U.S.N.L.M.) | |
|---|---|
| Dosing | 1 or 2 drops tid |
| Chem Specs | apraclonidine 0.5%, (1% singles) |
| Quantities | 5, 10ml, 0.1mL singles (2 per pouch) |
| Cost | 87.33/5ml (generic) |
| Class | alpha agonist |
| Action | Reduces aqueous production and increases uveoscleral outflow. |
| Usage | Indicated for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional IOP reduction. Indicated for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional IOP reduction. |
| Tachyphylaxis is common, so short-term use is recommended. | |
| Contraindications | Monoamine oxidase (MAO) inhibitor usage, severe cardiovascular disease, low blood pressure, or bradycardia. Hypersensitivity to apraclonidine, clonidine, or components. Monoamine oxidase (MAO) inhibitor usage, severe cardiovascular disease, low blood pressure, or bradycardia. Hypersensitivity to apraclonidine, clonidine, or components. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. |
| Pregnancy | Category C. Maternal toxicity in pregnant rats at 0.3 mg/kg/day (15 times the maximum recommended human dose). Category C. Maternal toxicity in pregnant rats at 0.3 mg/kg/day (15 times the maximum recommended human dose). |
| 1% singles intended for pre and post surgical treatment. | |
| Side-effects may include eyelid retraction, mydriasis, conjunctival blanching, dry mouth, headache, fatigue, lethargy and allergy (20 to 30%). BAK preserved. Side-effects may include eyelid retraction, mydriasis, conjunctival blanching, dry mouth, headache, fatigue, lethargy and allergy (20 to 30%). BAK preserved. |